PRASAD SUYASH 4
4 · Audentes Therapeutics, Inc. · Filed May 15, 2019
Insider Transaction Report
Form 4
PRASAD SUYASH
Senior VP & Chief Med Officer
Transactions
- Exercise/Conversion
Common Stock
2019-05-13$0.79/sh+10,000$7,900→ 28,236 total - Sale
Common Stock
2019-05-13$36.98/sh−9,946$367,761→ 18,290 total - Sale
Common Stock
2019-05-13$37.72/sh−54$2,037→ 18,236 total - Exercise/Conversion
Stock Option (right to buy)
2019-05-13−10,000→ 30,870 totalExercise: $0.79Exp: 2024-02-18→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $36.61 and the highest price at which shares were sold was $37.46. The reporting person undertakes to provide upon request to the staff of the Securities Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events.